Lineage Cell Therapeutics
LCTX
59 hedge funds and large institutions have $114M invested in Lineage Cell Therapeutics in 2014 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
62% more capital invested
Capital invested by funds: $70.1M → $114M (+$43.7M)
7.93% more ownership
Funds ownership: 37.54% → 45.47% (+7.9%)
4% more funds holding
Funds holding: 57 → 59 (+2)
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
39% less call options, than puts
Call options by funds: $207K | Put options by funds: $339K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$13.5M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$5.37M |
| 3 |
AG
Artal Group
Luxembourg
|
+$4.3M |
| 4 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
+$4.3M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$715K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSCM
Wellington Shields Capital Management
New York
|
-$857K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$389K |
| 3 |
Morgan Stanley
New York
|
-$262K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$220K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$106K |
LCTX Hedge Fund Activity: Q4 2014 in Review
59 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2014, worth a combined $114M — up 62% from $70.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LCTX positions and 6 closed out — a net gain of 4 holders — while 17 added to existing stakes and 16 trimmed.
The largest buyer was Broadwood Capital, adding an estimated $13.5M. The largest seller was Wellington Shields Capital Management, exiting entirely with an estimated $857K sold.
- 59 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2014, up from 57 in Q3 2014.
- Funds reported $114M of Lineage Cell Therapeutics stock for Q4 2014, up 62% quarter-over-quarter.
- 10 funds opened new Lineage Cell Therapeutics positions in Q4 2014 and 6 closed out, a net change of +4 holders.
- The largest Lineage Cell Therapeutics buyer in Q4 2014 was Broadwood Capital, an estimated $13.5M added.
- The largest Lineage Cell Therapeutics seller in Q4 2014 was Wellington Shields Capital Management, an estimated $857K sold.
Based on aggregated 13F filings for Q4 2014.